Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer

This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer

Inclusion Criteria:

• females, 18 or older
• recurrent, locally advanced, or metastatic breast cancer with expression of ER/PR receptor and/or overexpression of Her2/neu
• paraffin-embedded tissue block must be available
• measurable disease
• prior chemotherapy with an anthracycline and/or a taxane (neoadjuvant, adjuvant, or metastatic setting)
• 0, 1 or 2 chemotherapies in the metastatic setting
• adequate organ function

Exclusion Criteria:

• Metastatic disease confined to bone only
• Symptomatic central nervous system (CNS) metastasis
• Concurrent medical condition which may increase the risk of toxicity
• Unable to take oral medication